Abstract
Bacteria surviving within leukocytes are protected from the lethal action of high concentrations of most antibiotics, which may explain, in part, the failure of bactericidal antibiotics to eradicate staphylococci from abscesses. Since rifampin is unique in its ability to kill intraleukocytic bacteria, the efficacy of this drug was tested in the treatment of staphylococcal infections in mice. Groups of mice infected intravenously with Staphylococcus aureus were treated with rifampin (20 mg/kg), procaine penicillin (937.5 mg/kg), or methicillin (200 mg/kg). All untreated mice died with disseminated visceral abscesses. After 10 days of therapy, survival in groups treated with penicillin and methicillin was 16 and 20%, respectively, whereas with rifampin it was 80% (P < 0.0005). Antibiotic concentrations in the serum of mice treated with penicillin, methicillin, or rifampin were bactericidal for the strain of S. aureus used. Serial bacterial counts of kidney, lung, and spleen homogenates showed that neither penicillin nor methicillin was able to eradicate staphylococci, whereas rifampin completely sterilized those organs in many mice. When abscess contents and infected peritoneal washings were incubated with high concentrations of penicillin, methicillin, or rifampin, only rifampin killed all of the bacteria. The capacity of rifampin to eradicate staphylococci from pus in vitro and from abscesses in mice appears to be related to the ability of rifampin to kill intraleukocytic bacteria.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alexander J. W., Good R. A. Effect of antibiotics on the bactericidal activity of human leukocytes. J Lab Clin Med. 1968 Jun;71(6):971–983. [PubMed] [Google Scholar]
- Arioli V., Pallanza R., Furesz S., Carniti G. Rifampicin: a new rifamycin. I. Bacteriological studies. Arzneimittelforschung. 1967 May;17(5):523–529. [PubMed] [Google Scholar]
- Batten J. Rifampicin in treatment of experimental tuberculosis in mice. Tubercle. 1969 Sep;50(3):294–298. doi: 10.1016/0041-3879(69)90054-3. [DOI] [PubMed] [Google Scholar]
- Hoeprich P. D., Martin C. H. Effect of tetracycline, polymyxin B, and rifampin on phagocytosis. Clin Pharmacol Ther. 1970 May-Jun;11(3):418–422. doi: 10.1002/cpt1970113418. [DOI] [PubMed] [Google Scholar]
- Holmes B., Quie P. G., Windhorst D. B., Pollara B., Good R. A. Protection of phagocytized bacteria from the killing action of antibiotics. Nature. 1966 Jun 11;210(5041):1131–1132. doi: 10.1038/2101131a0. [DOI] [PubMed] [Google Scholar]
- Kunin C. M., Brandt D., Wood H. Bacteriologic studies of rifampin, a new semisynthetic antibiotic. J Infect Dis. 1969 Feb;119(2):132–137. doi: 10.1093/infdis/119.2.132. [DOI] [PubMed] [Google Scholar]
- Mandell G. L., Vest T. K. Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies. J Infect Dis. 1972 May;125(5):486–490. doi: 10.1093/infdis/125.5.486. [DOI] [PubMed] [Google Scholar]
- McCabe W. R., Lorian V. Comparison of the antibacterial activity of rifampicin and other antibiotics. Am J Med Sci. 1968 Oct;256(4):255–265. doi: 10.1097/00000441-196810000-00007. [DOI] [PubMed] [Google Scholar]
- ROGERS D. E., TOMPSETT R. The survival of staphylococci within human leukocytes. J Exp Med. 1952 Feb;95(2):209–230. doi: 10.1084/jem.95.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- SHAFFER J. M., KUCERA C. J., SPINK W. W. The protection of intracellular brucella against therapeutic agents and the bactericidal action of serum. J Exp Med. 1953 Jan;97(1):77–90. doi: 10.1084/jem.97.1.77. [DOI] [PMC free article] [PubMed] [Google Scholar]